Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Feb 26;32(10):1181-6. doi: 10.1016/j.vaccine.2013.09.060. Epub 2013 Oct 9.

Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Author information

1
Department of Allergy, National Hospital Organization Tokyo National Hospital, Japan.
2
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
3
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan.
4
International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Japan.
5
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan. Electronic address: oishik@nih.go.jp.

Abstract

An observational study was conducted to determine immunogenicity before and after primary and secondary vaccinations with 23-valent pneumococcal polysaccharide vaccine in a cohort of 40 elderly patients with chronic lung diseases. Safety of this vaccine was also compared between primary and secondary vaccination. We analyzed serotype-specific immunoglobulin G (IgG) and the opsonization index (OI) for serotypes 6B, 14, 19F, and 23F and compared adverse local and systemic reactions. The levels of serotype-specific IgG and the OIs significantly increased 1 month after primary and secondary vaccinations. Peak levels of IgG after secondary vaccination were 5-20% lower than those after primary vaccination, while serotype-specific OIs after secondary vaccination were comparable with those after primary vaccination. The levels of serotype-specific IgG required for 50% killing significantly decreased 1 month after vaccination. These values for serotypes 14, 19F, and 23F were slightly elevated immediately before secondary vaccination, but those for serotype 6B did not change. After secondary vaccination, these values declined slightly for serotypes 14, 19F, and 23F and remained low for serotype 6B. Although self-limited local and systemic reactions were more frequent after secondary vaccination compared with primary vaccination, no serious systemic reaction was found after either vaccination. Our data suggest a sustained functional serotype-specific IgG after primary and secondary vaccination and confirmed the safety of secondary vaccination among elderly individuals with chronic lung disease.

KEYWORDS:

Opsonophagocytic activity; Pneumococcal polysaccharide vaccine; Revaccination; Serotype-specific IgG

PMID:
24120483
DOI:
10.1016/j.vaccine.2013.09.060
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center